InsidersTradesSigma
Track the Adlai Nortye Ltd. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €922.8m. The latest transaction was disclosed on 10 June 2026 (J). Among the most active insiders: Ji Ping. All data is openly available.
Analysts rate Adlai Nortye Ltd. Strong Buy (bullish), based on 5 analysts. Average price target: US$28.60.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Adlai Nortye Ltd. es una compañía biofarmacéutica enfocada en el desarrollo de tratamientos innovadores para el cáncer. Cotiza en NASDAQ bajo el símbolo ADLN.